CliffBio
biologic

Yuflyma

adalimumab-aaty

Loss of exclusivity—loss of exclusivity
CompanyCelltrion →See this company's full patent-cliff portfolio

Drug detail

Brand nameYuflyma
Active ingredientadalimumab-aaty
Strength40MG/0.4ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalMay 2023
Marketing statusRx

More from Celltrion

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.